61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Eli Lilly and Co.
Closed
Sector Healthcare
726.05 -4.28
Overview
Share price change
24h
Min
725.01
Max
733.85
Income | -2B 970M |
|---|---|
Sales | 137M 11B |
P/E Sector Avg | 109.11 59.526 |
EPS | 1.18 |
Dividend yield | 0.587 |
Profit margin | 8.482 |
EBITDA | 786M 4.9B |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +41.1 upside |
Dividend yield Sector Avg | 0.59% 2.33% |
|---|---|
Next Earnings | 6 Feb 2025 |
Next Dividend date | 10 Mar 2025 |
Next Ex Dividend date | 14 Feb 2025 |
Market Cap | -35B 712B |
|---|---|
Previous open | 730.33 |
Previous close | 726.05 |
News Sentiment
By Acuity
42%
58%
138 / 392 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Eli Lilly and Co. Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Eli Lilly and Co. Forecast
Price Target
By TipRanks
41.1% upside
12 Months Forecast
Average 1,024 USD 41.1%
High 1,250 USD
Low 900 USD
Based on 17 Wall Street analysts offering 12 month price targets forEli Lilly and Co. - Dist in the last 3 months.
Sentiment
By Acuity
138 / 392 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Eli Lilly and Co.
Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products include Cymbalta, Emgality, Reyvow, Strattera and Zyprexa. Its Oncology products include Alimta, Cyramza, Erbitux and Verzenio. Other product includes Cialis, for the tratment of erectile dysfunction and benign prostatic hyperplasia. The Company manufacture and distribute its products through facilities in the United States, Puerto Rico, and 8 other countries. Its products are sold in approximately 120 countries.
